Galactooligosaccharides (GOS)
Galacto-Oligosaccharides (B-GOS / Bimuno) · also known as GOS, Galacto-oligosaccharides, Human milk oligosaccharide analog, Bimuno
Galactooligosaccharides are fermented by colonic bacteria. In human studies, breath hydrogen rose, which supports fermentation in the gut, and bifidobacteria increased at 15 g/day. Fecal and plasma short-chain fatty acids did not rise noticeably, and there is no direct human evidence for effects on luminal pH or pathogenic bacteria.
Clinical uses and human evidence
Irritable bowel syndrome
Studies (2)
- Silk 2009 · Aliment Pharmacol Ther · Randomized crossover trial · n=44 — Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome
- Wilson 2020 · Am J Gastroenterol · RCT · n=69 — β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria
Constipation
Studies (2)
- Schoemaker 2022 · Nutrients · RCT · n=132 — Prebiotic Galacto-Oligosaccharides Impact Stool Frequency and Fecal Microbiota in Self-Reported Constipated Adults: A Randomized Clinical Trial
- Vulevic 2018 · Neurogastroenterol Motil · Randomized crossover trial · n=83 — Effect of a prebiotic galactooligosaccharide mixture (B-GOS®) on gastrointestinal symptoms in adults selected from a general population who suffer with bloating, abdominal pain, or flatulence
Diarrhea (including antibiotic-associated diarrhea)
Studies (2)
- Hasle 2017 · J Travel Med · RCT · n=523 — Can a galacto-oligosaccharide reduce the risk of traveller's diarrhoea? A placebo-controlled, randomized, double-blind study
- Drakoularakou 2010 · Eur J Clin Nutr · RCT · n=159 — A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea
Mechanisms of action
Colonic short-chain fatty acid (SCFA/butyrate) fermentation substrate and receptor activation
Galactooligosaccharides are fermented by several types of colonic bacteria. In human randomized trials, breath hydrogen rose, which supports fermentation in the gut. However, fecal and plasma short-chain fatty acids did not rise noticeably, and there is no direct human evidence that the fermentation products affect luminal pH or pathogenic bacteria.
References (2)
- Alles 1999 · Human RCT: GOS was not recovered in feces; breath hydrogen rose in the high-dose group, supporting intestinal fermentation; fecal short-chain fatty acids did not change significantly
- Canfora 2017 · Human RCT: 15 g/day GOS increased bifidobacteria, but fecal and plasma short-chain fatty acids did not rise significantly
Secretion of intestinal mucin (MUC2) and the protective mucus gel layer
In animal studies, galactooligosaccharides can lessen damage to the colonic mucus layer caused by a Western diet. In human cell experiments, they can upregulate MUC2 and other genes in goblet-like cells. It has not been reliably shown, however, that routine supplementation increases goblet cell secretion or mucus thickness in humans.
Epithelial tight junction (ZO-1 / Occludin) reinforcement and barrier repair
In animal models of intestinal injury, galactooligosaccharides can upregulate tight junction-related genes such as ZO-1 and occludin. Direct human evidence is insufficient, and changes in inflammatory or stress markers do not prove that tight junctions were repaired.